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Abstract: The age at diagnosis of pulmonary arterial hypertension (PAH) and the prevalence of cardiovascu-
lar (CV) risk factors are increasing. We sought to determine whether the response to drug therapy was
influenced by CV risk factors in PAH patients. We studied consecutive incident PAH patients (n = 146)
between January 1, 2008, and July 15, 2011. Patients were divided into two groups: the PAH–No CV group
included patients with no CV risk factors (obesity, systemic hypertension, type 2 diabetes mellitus, perma-
nent atrial fibrillation, mitral and/or aortic valve disease, and coronary artery disease), and the PAH-CV
group included patients with at least one. The response to PAH treatment was analyzed in all the patients
who received PAH drug therapy. The PAH–No CV group included 43 patients, and the PAH-CV group
included 69 patients. Patients in the PAH–No CV group were younger than those in the PAH-CV group
(P < 0.0001). In the PAH–No CV group, 16 patients (37%) improved on treatment and 27 (63%) did not
improve, compared with 11 (16%) and 58 (84%) in the PAH-CV group, respectively (P = 0.027 after
adjustment for age). There was no difference in survival at 30 months (P = 0.218). In conclusion, in addition
to older age, CV risk factors may predict a reduced response to PAH drug therapy in patients with PAH.
Keywords: pulmonary arterial hypertension, cardiovascular risk factors, pulmonary arterial hypertension–
targeted treatment.
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INTRODUCTION
Pulmonary arterial hypertension (PAH) is a rare progres-
sive disease that leads to right heart failure and death.1
PAH drug therapies have significantly improved symp-
toms, hemodynamics, and exercise capacity in patients
with PAH.2-4 The age at diagnosis of PAH has been grad-
ually shifting to older age over the last decade,5-8 while
the United Kingdom and Ireland registry has identified a
less good outcome in older compared with younger pa-
tients,7 and COMPERA (Comparative, Prospective Registry
of Newly Initiated Therapies for Pulmonary Hyperten-
sion) has shown that older patients respond less well to
PAHdrugs.8
As patients age, there is an increase in the prevalence of
cardiovascular (CV) risk factors predisposing to left heart
disease.6-8 Postcapillary pulmonary hypertension (PH) is
driven by left heart disease and according to current guide-
lines should not be treated by PAH drugs.9,10 Given that
most of the randomized controlled trials of PAH drug ther-
apies have included younger patients,2-4 it is an open ques-
tion whether these therapies are equally beneficial in
patients with coexisting CV risk factors that may affect the
left heart.
In this study, we sought to determine whether the
response to PAH drug therapy in patients with PAH was
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influenced by conventional CV risk factors. We compared
PAH patients to those without CV risk factors as well as
to patients with PH due to left heart disease to examine
whether they share some of the characteristics of left
heart disease.
METHODS
Study design: definitions
This study was conducted in the National Pulmonary Hy-
pertension Service at Hammersmith Hospital, London,
which is one of seven nationally designated referral cen-
ters in the United Kingdom. We collected and examined
data on consecutive, incident PH patients seen and investi-
gated between January 1, 2008, and July 15, 2011. Incident
PH patients were defined as patients with PH presenting
for the first time to a specialist PH center who had never
received PAH drug therapy. All patients underwent inves-
tigation of PH according to current guidelines.9,10 PH was
defined by mean pulmonary arterial pressure (mPAP) of
≥25mmHg on cardiac catheterization.9,10
We divided the patients into two groups according to
the presence of CV risk factors: group 1 had no risk fac-
tors, and group 2 had at least one risk factor (Fig. 1).
These risk factors included obesity, systemic hyperten-
sion, type 2 diabetes mellitus, permanent atrial fibrillation,
aortic and/or mitral valve disease, and coronary artery
disease.11-16
Systemic hypertension was defined by systolic blood
pressure of >140 mmHg and/or diastolic blood pressure
of >90 mmHg recorded in more than two measure-
ments, by physician-documented history of hypertension,
or by chronic use of antihypertensive medications. Diabe-
tes mellitus was defined by the presence of a physician-
documented history or prescription of oral hypoglycemic
agents or insulin for the treatment of hyperglycemia. Per-
manent atrial fibrillation was defined as atrial fibrillation
accepted by patient and physician.17 Coronary artery dis-
ease was defined by the presence of physician-documented
history, known coronary stenosis of >50%, prior history of
myocardial infarction, previous percutaneous coronary in-
tervention, coronary artery bypass grafting, or abnormal
stress test consistent with myocardial ischemia. Obesity
was defined by a body mass index of ≥30 (calculated as
the weight in kilograms divided by the square of height in
Figure 1. Consort diagram of the study. PH: pulmonary hypertension; CV: cardiovascular; PVH: pulmonary venous hypertension;
CTEPH: chronic thromboembolic pulmonary hypertension; PAH: pulmonary arterial hypertension.
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meters). Valve disease was defined by at least moderate
mitral stenosis, mitral regurgitation, aortic stenosis, and/
or aortic regurgitation demonstrated by echocardiography
according to current guidelines.18
We further divided the patients of groups 1 and 2 into
two additional groups according to the presence of pre- or
postcapillary PH (Fig. 1). Precapillary PH was defined
by mPAP of ≥25 mmHg, pulmonary arterial wedge pres-
sure (PAWP) of ≤15 mmHg, and/or left ventricular end-
diastolic pressure (LVEDP) of ≤16 mmHg and normal or
reduced cardiac output, and postcapillary PH was defined
as mPAP of ≥25 mmHg, PAWP of >15 mmHg, and/or
LVEDP of >16 mmHg and normal or reduced cardiac
output.10,19
As the number of patients with left ventricular systolic
dysfunction who were referred to our center was small,
we excluded them on the basis of left ventricular ejec-
tion fraction of ≤50% measured on the echocardiogram
by Simpson’s method.19 We also excluded patients with
chronic thromboembolic PH and PH due to lung disease
and/or hypoxia.
Variables analyzed
We analyzed parameters identified and obtained during
the first visit to the clinic with the exception of hemo-
dynamic data. As the time between the first visit to the
clinic and catheterization did not exceed 3 weeks, we as-
sumed that these variables had not significantly changed
in this time.
We conducted a 6-minute walk test (6MWT) according
to American Thoracic Society guidelines.20 We exam-
ined the electrocardiogram (ECG) and determined heart
rhythm, the presence of complete right bundle branch
block (defined by rSR′ or qRs morphology in V1 lead and
QRS duration of >120 ms), a dominant R wave in V1 lead
(R > S), right ventricular strain (ST segment deviation
and T-wave inversion in V1–V3),
21 and right axis devia-
tion (QRS axis of >100°).
All echocardiograms recorded at the first visit were
reviewed. The measurements were made according to
American Society of Echocardiography guidelines.22 We
also calculated the ratio of end-diastolic basal right ven-
tricular diameter (at the tips of the tricuspid valve) to
end-diastolic basal left ventricular diameter (at the tips of
the mitral valve) in the 4-chamber view (RV/LV ratio) as
a marker of the ventricular predominance in terms of
dimensions.23 The echocardiographic variables that had
not been measured in the first instance were measured
retrospectively off-line, on stored images. All of the echo-
cardiographic variables were measured independently by
two echocardiographers who were masked to the hemo-
dynamic data.
Finally, we analyzed hemodynamics. Cardiac output
was measured using the Fick principle with estimated
oxygen consumption, cardiac index was calculated as car-
diac output divided by body surface area, and pulmonary
vascular resistance (PVR) was calculated as the difference
between mPAP and PAWP divided by pulmonary flow.
Transpulmonary gradient was calculated as mPAP minus
PAWP, and diastolic pulmonary pressure difference was
calculated as diastolic pulmonary arterial pressure minus
PAWP.
Response to treatment
The majority of patients with PAH received PAH drug
therapies. The reasons why some of the PAH patients
were not started on treatment included drug therapy not
being funded at that time in England for New York
Heart Association (NYHA) functional class II or patients
having PAH related to conditions in which the underly-
ing cause needed to be treated prior to considering PAH
drugs (e.g., closure of atrial septal defects, immunosup-
pression for systemic lupus erythematosus).
We identified the response to PAH drugs at the last
available patient visit to the PH clinic compared with the
baseline before treatment was commenced. Improvement
on treatment was defined as a combined improvement
in NYHA functional class plus an increase in 6MWT dis-
tance (6MWTD) of ≥15% compared with baseline. Pa-
tients who failed to meet these criteria were classified as
having no improvement on treatment.
Worsening on treatment was defined as a combined
deterioration of NYHA functional class after treatment or
failure to improve from NYHA functional class IV plus
a decrease in 6MWTD of ≥15% or death. The patients
who did not meet the criteria of improvement or worsen-
ing were considered to be stable.
Combination therapy included a phosphodiesterase
5 inhibitor plus an endothelin receptor antagonist or a
phosphodiesterase 5 inhibitor and/or an endothelin re-
ceptor antagonist plus prostacyclin.
Statistical analysis
PH patients were assigned to one of four groups: PAH
with no CV risk factors (PAH–No CV group), PAH with
CV risk factors (PAH-CV group), PH related to left heart
disease with CV risk factors (PVH-CV group), and PH
with postcapillary hemodynamics and no CV risk factors
(PVH–No CV group; Fig. 1).
We compared the groups as follows: PAH–No CV to
PAH-CV and PAH-CV to PVH-CV. The PVH–No CV group
included only a small number of patients (7 patients) with
variable etiology of left heart disease and was not analyzed
further.
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Categorical data are expressed as number of patients
(%), while continuous data are presented as median (inter
quartile range), as some were not normally distributed.
Between-group differences were assessed by the χ2 test
for categorical variables and by the Kruskal-Wallis test for
continuous variables.
As we compared a large number of variables between
the groups, we applied a post hoc Bonferroni correction
for multiple comparisons, which raised the threshold of
statistical significance to 0.001. We report a trend toward
a difference when a P value was <0.05. We did not apply
a Bonferroni correction for the comparison of response
to treatment.
As patients in the PAH-CV group were significantly
older than those in the PAH–No CV group, we performed
age adjustment using logistic regression to determine dif-
ferences in clinical characteristics, response to PAH treat-
ment, and survival between these groups.
Survival was estimated from the time of PH diagnosis
to all-cause mortality or end of study. Univariate Cox re-
gression was used to test for differences between survival
probabilities of different PH groups. For the survival anal-
ysis, all patients were censored at a fixed date (March 13,
2013) or on the date of death if earlier. All statistical anal-
yses were performed using SPSS (ver. 10).
RESULTS
PAH–No CV group versus PAH-CV group
Differences between the PAH–No CV and PAH-CV
groups are listed in Tables 1 and 2. Patients in the PAH-
CV group were significantly older than those without CV
risk factors. There was no difference in the types of PAH,
symptoms, clinical signs, or 6MWTD across the groups
(Table 1). The ECG findings were not different after ad-
justment for age and Bonferroni correction (Table 2).
There was no significant difference in medications, brain
natriuretic peptide levels, and echocardiographic variables.
On echocardiogram there was a trend toward greater left
ventricular posterior wall thickness and left atrial diameter
in the PAH-CV group, while for hemodynamics there was
a trend toward higher PAWP and LVEDP (Table 2).
Response to treatment: survival analysis
Forty-three (86%) of 50 patients were started on PAH-
targeted treatment in the PAH–No CV group, while 75
(78%) of 96 were started in the PAH-CV group. The
mean follow-up time was 20 ± 11.3 months in the PAH–
No CV group and 16.4 ± 10.9 months in the PAH-CV
group (P = 0.290). Patients in the PAH–No CV group
were 3.3 times more likely to show improvement on
treatment than were patients in the PAH-CV group
(odds ratio, 3.294 [95% confidence interval, 1.11–9.72];
P = 0.002 before and 0.027 after adjustment for age;
Table 3). The difference in response to treatment was
driven by less improvement in the PAH-CV group rather
than more worsening. The number of CV risk factors
did not significantly affect the response to PAH thera-
pies. There was no difference between PAH-specific medi-
cations (monotherapy or combination therapy) prescribed
in the two groups (Table 4).
The mean follow-up time for survival analysis was
32.8 ± 16.3 months for the PAH–No CV group and 28.2 ±
13 months for the PAH-CV group. Over 3 years, there
were 13 deaths (26%) and the mean survival time was
30 months (SE, 1.529) in the PAH–No CV group, while
there were 34 deaths (35.4%) with a mean survival time
of 28.7 months (SE, 1.119) in the PAH-CV group (P =
0.245). Over 5 years, there were 15 deaths (30%) and the
mean survival time was 46.2 months (SE, 2.962) in the
PAH–No CV group, while there were 38 deaths (39.5%)
and the mean survival time was 42 months (SE, 2.290) in
the PAH-CV group. The difference between the groups
was not significant (P = 0.218).
PAH-CV group versus PVH-CV group
There was no significant difference in age and sex distri-
bution between the PAH-CV and PVH-CV groups. Pa-
tients in the PVH-CV group had a significantly greater
number of CV comorbidities (median, 2 vs. 1.5; P <
0.0001; Fig. 2). The two groups had no difference in symp-
toms, symptom severity, or clinical signs. Differences in
ECG, echocardiogram, and hemodynamics are shown in
Table 2.
The mean follow-up time for the PVH-CV group was
26.2 ± 13 months. There were 29 deaths (26.3%), and
the mean survival time was 47.7 months (SE, 2.330).
Compared with the PAH-CV group, there was a trend
toward better survival, although not statistically signifi-
cant, in the PVH-CV group (P = 0.075).
DISCUSSION
This is the first study to examine the response to PAH
therapies according to the presence of CV risk factors
related to left heart disease. This study showed that PAH
patients with CV risk factors are less likely to respond
well in terms of their symptom severity and exercise ca-
pacity 16 months after starting PAH drug therapies than
are PAH patients without CV risk factors.
Data from COMPERA8 have shown that elderly idio-
pathic PAH patients respond less well to PAH therapies
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Table 1. Comparison of demographic and clinical data
P value
Variable
PAH–No CV
(n = 50)
PAH-CV
(n = 96)
PVH-CV
(n = 110)
PAH–No CV
vs. PAH-CV
PAH-CV vs.
PVH-CV
Demographics
Age, years 46 (34–64) 65 (59–73) 70 (60–76) <0.0001 0.045
Female, no. (%) 30 (60) 57 (59.4) 69 (62.7) 0.942 0.622
BMI 25 (21.2–26.8) 30.5 (24.6–35.5) 29.7 (26–38) <0.0001/<0.0001 0.215
BSA, m2 1.73 (1.6–1.9) 1.83 (1.7–2.05) 1.91 (1.78–2.12) <0.0001/<0.0001 0.043
Cardiovascular comorbidities, no. (%)
Obesity . . . 49 (52.7) 46/92 (50) 0.715
Systemic hypertension . . . 56 (58.3) 88 (80) 0.001
Diabetes mellitus . . . 28 (29.2) 48 (43.6) 0.032
Atrial fibrillation . . . 21 (21.9) 45 (40.9) 0.003
Valve disease . . . 9 (9.4) 17 (15.5) 0.190
Coronary artery disease . . . 25 (26) 34 (30.9) 0.441
No. of cardiovascular risk factors . . . 1.5 (1–3) 2 (2–4) <0.0001
PAH type, no. (%)
Idiopathic PAH 23 (46) 59 (61.5) . . . 0.222/0.874a
Associated with connective tissue disease 9 (18) 19 (19.8) . . .
Associated with congenital heart disease 5 (10) 6 (6.3) . . .
Portopulmonary 5 (10) 5 (5.2) . . .
PVOD 2 (4) 3 (3.1) . . .
Other 6 (12) 4 (4.2) . . .
NYHA functional class, no. (%)
I 0 (0) 1 (1) 1 (0.9) 0.003/0.043b 0.051b
II 15 (30) 7 (7.3) 16 (14.7)
III 22 (44) 59 (61.5) 76 (68.8)
IV 13 (26) 29 (30.2) 17 (15.6)
Clinical symptoms and signs
Orthopnea, no. (%) 3/28 (10.7) 17/69 (24.6) 23/74 (31.1) 0.125/0.314 0.391
Heart rate, bpm 82 (75–98) 80 (72–92) 79 (69–89) 0.247/0.517 0.085
Systolic blood pressure, mmHg 128 (115–133) 138 (120–158) 147 (132–160) 0.003/0.042 0.024
Peripheral edema, no. (%) 19 (38) 42/95 (44.2) 66 (60) 0.472/0.908 0.020
Six-minute walk test
Distance, m 276 (78–405) 180 (96–276) 180 (93–310) 0.021/0.321 0.976
Pretest SpO2, % 97 (93–98) 95 (91–98) 96 (93–97) 0.153/0.713 0.356
Posttest SpO2, % 94 (85–97) 91 (86–97) 93 (90–96) 0.520 0.424
BNP, ng/L 274 (124–762) 395 (101.4–1127) 324 (185–817) 0.280 0.467
Medications, no. (%)
Diuretics 22 (44) 62 (64.6) 88 (80) 0.017/0.335 0.013
Warfarin 15 (30) 33 (34.4) 49 (44.5) 0.593/0.795 0.137
Angiotensin-converting enzyme inhibitors 5 (10) 35 (36.5) 41 (37.3) 0.001/0.054 0.904
Angiotensin II AT1 receptor blockers 0 (0) 13 (13.5) 38 (34.5) 0.006/0.999 <0.0001
Digoxin 3 (6) 9 (9.5) 24 (21.8) 0.471/0.553 0.016
β-Blockers 3 (6) 21 (21.9) 47 (42.7) 0.014/0.179 0.001
Statins 4 (8) 36 (37.5) 61 (56) 0.0001/0.007 0.008
Note: All continuous variables are expressed as median (interquartile range). In the P value column for PAH–No CV versus PAH-
CV, the second P value is after age adjustment. After Bonferroni correction, the statistical threshold is P ≤ 0.001. P values in
boldface type indicate statistically significant differences. PAH: pulmonary arterial hypertension; CV: cardiovascular risk factors;
PVH: pulmonary venous hypertension; BMI: body mass index; BSA: body surface area; PVOD: pulmonary venoocclusive disease;
NYHA: New York Heart Association; SpO2: finger oxygen saturation; BNP: brain natriuretic peptide.
a Refers to all types of PAH.
b Refers to all World Health Organization functional classes.
Table 2. Comparison of electrocardiographic, echocardiographic, and hemodynamic data
P value
Variable
PAH–No CV
(n = 50)
PAH-CV
(n = 96)
PVH-CV
(n = 110)
PAH–No CV
vs. PAH-CV
PAH-CV vs.
PVH-CV
Electrocardiography
Sinus rhythm, no. (%) 49/49 (100)a 72/93 (77.4)b 61/105 (57.5)c <0.0001/0.998 0.003
RBBB, no. (%) 5/49 (10.2) 7/93 (7.5) 5/105 (4.8) 0.586/0.337 0.416
R wave dominant in lead V1, no. (%) 30/49 (61.2) 37/93 (39.8) 19/105 (18.1) 0.015/0.424 0.001
Right ventricular strain, no. (%) 31/49 (63.3) 40/93 (43) 23/105 (21.9) 0.022/0.541 0.001
Right axis deviation, no. (%) 31/49 (63.3) 32/93 (34.4) 15/105 (14.3) 0.001/0.011 0.001
PR interval, ms 152 (143–161) 164 (150–182) 154 (140–179) 0.006/0.045 0.110
QRS duration, ms 97 (84–108) 94 (86–104) 94 (84–106) 0.607/0.845 0.934
Echocardiography
Left ventricular end-diastolic
diameter, cm 4.3 (3.8–4.6) 4.2 (3.9–4.6) 4.7 (4.2–5.1) 0.901/0.678 <0.0001
Interventricular septal thickness, cm 0.9 (0.7–1) 1.0 (0.9–1.1) 1.0 (0.9–1.1) 0.007/0.387 0.462
Left ventricular posterior wall
thickness, cm 0.9 (0.8–1) 1.0 (0.9–1.1) 1.0 (0.9–1.1) <0.0001/0.014 0.353
E/E′ ratio 5 (3.9–7.3) 7.5 (5–11) 9.1 (7–14) 0.091/0.547 0.009
RV/LV ratio 1.35 (1.07–1.68) 1.22 (0.84–1.5) 0.92 (0.79–1.15) 0.120/0.303 <0.0001
Peak velocity of tricuspid
regurgitation, m/s 4.2 (3.7–4.6) 4.1 (3.6–4.5) 3.7 (3.3–4.1) 0.147/0.375 <0.0001
Right atrial volume, mL 80 (65–100) 105 (76–136) 105 (78–124) 0.029/0.507 0.713
Left atrial diameter, cm 3 (3–4) 4 (3–4) 5 (4–5) 0.001/0.024 <0.0001
LAVI 36 (26–47) 44 (31–57) 55 (38–70) 0.046/0.921 0.001
TAPSE, mm 15 (11–19) 15 (13–20) 16 (13–21) 0.608/0.587 0.803
Right ventricular TDI S wave, cm/s 9 (8.6–11) 11 (9–12) 9 (8–12) 0.073/0.195 0.041
Right ventricular Tei index 0.7 (0.57–0.8) 0.6 (0.47–0.74) 0.5 (0.38–0.65) 0.142/0.338 0.067
Pericardial effusion, no. (%) 9 (18) 23 (24) 9 (8.2) 0.409/0.739 0.002
Hemodynamics
mPAP, mmHg 51 (44–59) 43 (33–56) 41 (33–53) 0.023/0.998 0.284
LVEDP, mmHg 8 (6–10) 10 (8–13) 18 (17–22) 0.001/0.007
PAWP, mmHg 10 (8–12) 12 (9–15) 21 (17–25) 0.002/0.008
mRAP, mmHg 7 (5–10) 10 (7–14) 15 (11–18) 0.023/0.016 <0.0001
RVEDP, mmHg 10 (6–14) 10 (7–15) 15 (9–18) 0.602/0.196 <0.0001
Transpulmonary gradient, mmHg 40 (32–47) 34 (20–44) 18 (12–28) 0.006/0.372
Diastolic pulmonary pressure
difference, mmHg 22 (11–30) 18 (9–27) 2 (−3 to 11) 0.248/0.375
Cardiac index 2.2 (1.8–2.9) 2.2 (1.9–2.8) 2.1 (1.8–2.8) 0.893/0.926 0.564
Pulmonary vascular resistance,
Wood units 11 (6–15) 8 (5–13) 5 (3–8) 0.039/0.732 <0.0001
Note: All continuous variables are expressed as median (interquartile range). In the P value column for PAH–No CV versus PAH-
CV, the second P value is after age adjustment. After Bonferroni correction, the statistical threshold is P ≤ 0.001. P values in boldface
type indicate statistically significant differences. PAH: pulmonary arterial hypertension; CV: cardiovascular risk factors; PVH: pulmo-
nary venous hypertension; RBBB: right bundle branch block; RV/LV ratio: right ventricular basal end-diastolic/left ventricular basal
end-diastolic diameter (in the 4-chamber view); LAVI: left atrial volume index; TAPSE: tricuspid annular plane systolic excursion;
TDI: tissue Doppler imaging; mPAP: mean pulmonary arterial pressure; LVEDP: left ventricular end-diastolic pressure; PAWP:
pulmonary arterial wedge pressure; mRAP: mean right atrial pressure; RVEDP: right ventricular end-diastolic pressure.
a One patient had paced rhythm.
b Two patients had paced rhythm, and in one case an electrocardiogram was not available.
c Five patients had paced rhythm.
than younger ones. Age difference and less aggressive
PAH treatment in the elderly group were mentioned as
possible reasons for this difference. In our study, even
after adjustment for age the less effective response to
treatment in the older PAH group with CV comorbidi-
ties remained, while there was no difference in the
drugs prescribed for the two groups.
Our study has shown that some of the phenotypic
features of the PAH-CV group lie between those of the
PAH–No CV and PVH-CV groups: compared with the
PAH–No CV group, the PAH-CV group had a trend to-
ward higher PAWP and LVEDP, which by definition are
lower in the PVH-CV group. Increasing PAWP may in-
crease right ventricular afterload and contribute to right
ventricular dysfunction.24 In addition, the PAH-CV group
had values for PVR and left atrial size between those of
the PAH–No CV and PVH-CV groups.
One possible interpretation for the different response
to PAH therapies in our study would be a possible del-
eterious effect of these drugs in the presence of left
heart disease. The trials of intravenous epoprostenol and
bosentan in patients with left ventricular systolic dysfunc-
tion have shown either a negative or no effect on clinical
outcomes.25-27 On the contrary, sildenafil in patients with
left ventricular systolic dysfunction has been shown to
improve exercise capacity and hemodynamics.28,29 The
recent LEPHT study (Study to Test the Effects of Riociguat
in Patients with Pulmonary Hypertension Associated with
Left Ventricular Systolic Dysfunction) with riociguat, a
novel soluble guanylate cyclase stimulator, in patients
with left systolic heart failure did not achieve its primary
end point (decrease in mPAP) despite an improvement in
other hemodynamic parameters (cardiac index, PVR),
while it was not powered to detect any clinical outcomes in
the study groups.30 In our study, patients with left ven-
tricular systolic dysfunction were excluded; however, PAH
patients with CV risk factors may have masked left ven-
tricular diastolic dysfunction. Some of the PAH-CV group
characteristics, such as age, CV risk factors, heart failure
symptoms, left ventricular ejection fraction of >50%, and
dilated left atrium, meet the inclusion criteria used in ran-
domized clinical trials in patients with heart failure with
preserved ejection fraction (HFpEF).31-33 This suggests
that the PAH-CV group overlapped or may have consisted
of a subpopulation of patients with HFpEF who also have
precapillary PH at rest. The relatively poor efficacy of PAH
drugs in such patients would then be consistent with the
findings of the RELAX (Evaluating the Effectiveness of
Sildenafil at Improving Health Outcomes and Exercise
Ability in People with Diastolic Heart Failure) trial, which
showed that sildenafil failed to improve clinical status and
exercise capacity in patients with HFpEF but not specifi-
cally with PH.34 Whether the natural history of some of
the patients in the PAH-CV group is to develop postcap-
illary hemodynamics at a later stage is not clear. Our re-
sults would not be consistent, however, with the positive
results of sildenafil in selected patients with left ventricu-
lar hypertrophy, HFpEF, and PH, although exercise capac-
ity was not investigated in this study.35
The role of sildenafil has also been explored in the pres-
ence of CV comorbidities in animal models. In animals
with diabetic cardiomyopathy, impaired glucose intoler-
ance, triglyceridemia, and hypertensive cardiomyopathy,
sildenafil has had a beneficial effect on left ventricular
function.36-38 Although the effect on the function of the
right ventricle is not known, in light of these studies the
potential harmful effect of PAH drugs in the presence of
CV comorbidities seems to be a less likely explanation.
If the drugs themselves are not responsible for the
less good response of exercise capacity to them, then a
more restrained myocardium might provide an explana-
tion. In the PAH-CV group, the presence of CV risk fac-
tors may have caused coronary microvascular dysfunction,
Table 3. Response to pulmonary arterial hypertension (PAH)
drug therapy
PAH–No
CV group
(n = 43)
PAH-CV
group
(n = 69)
P value for
improvement vs.
no improvement
Improvement 16 (37) 11 (16) 0.002/0.027a
No improvement 27 (63) 58 (84)
Stable 14 (33) 31 (45)
Worsening 13 (30) 27 (39)
Note: Data are no. (%). CV: cardiovascular risk factors.
a After adjustment for age.
Table 4. Pulmonary arterial hypertension (PAH) medications
Medication
PAH–No CV
(n = 43)
PAH-CV
(n = 75)
P
value
Phosphodiesterase
5 inhibitors 36 (84) 62 (83) 0.356
Endothelin receptor
antagonists 21 (49) 39 (52) 0.289
Prostacyclin analogues 6 (14) 14 (19) 0.125
Combination therapy 19 (44) 38 (51) 0.176
Note: Data are no. (%). CV: cardiovascular risk factors.
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right ventricular ischemia (in addition to ischemia caused
by increased afterload), and diastolic dysfunction, exactly
as CV risk factors do in the left ventricle,39-41 resulting in
right ventricular dysfunction and exercise limitation not
responding to PAH drugs, which mainly act on pulmonary
vasculature. Sildenafil, in additional to its beneficial effect
on pulmonary vasculature, has been shown to have a posi-
tive direct effect on hypertrophied right ventricular myo-
cardium by increasing its contractility in humans,42 but it
was unable to prevent right ventricular diastolic dysfunc-
tion in animal models.43 Of note, sildenafil seems to play a
beneficial role in microvascular coronary dysfunction of
the left ventricle in women after a single dose, although its
long-term effects are not known.44
The worse response to treatment did not lead to worse
survival in our study. On the contrary, in COMPERA8
survival was significantly worse among elderly idiopathic
PAH patients than among younger ones after adjustment
for age. This difference could be attributed to the smaller
size and the shorter time of follow-up of our population
or to a much older population in COMPERA.
This study also examined whether the PAH-CV group
shared some common characteristics with the patients
with PVH-CV. The two groups had no age or sex differ-
ences. The PVH-CV group had a significantly greater prev-
alence of systemic hypertension and a trend toward more
atrial fibrillation, while the total number of CV risk factors
was significantly higher than in the PAH group (Fig. 2).
The PVH-CV patients were less likely to have a dominant
R wave on the ECG, while they had a larger left ventricle
with a smaller RV/LV ratio, a more dilated left atrium, and
a lower peak velocity of tricuspid regurgitation on the
echocardiogram. Finally, on cardiac catheterization the
PVH-CV patients had higher mean right atrial pressure
and right ventricular end-diastolic pressure but lower PVR,
with no difference in mPAP and cardiac index. These find-
ings are consistent with other studies examining pulmo-
nary venous hypertension45 and HFpEF46 with PH
populations. In terms of survival, the patients with
postcapillary PH had a trend toward better survival than
the two PAH groups, which is consistent with the ASPIRE
(Assessing the Spectrum of Pulmonary Hypertension Iden-
tified at a Referral Centre) registry.47
Study limitations
This is a single-center retrospective study, and for this
reason we recognize that the findings require verifica-
tion in other patient cohorts. Nevertheless, the findings
concerning less treatment efficacy in the PAH-CV group
are broadly consistent with registry data and add to an
understanding of why some patients respond less well to
drug therapy for PAH.
We chose to assess the response to treatment at the
patient’s last hospital visit rather than at a set time to
describe at least a medium-term rather than simply a
short-term response. While this does mean we followed
up patients after different periods on treatment, we did
not do so within 3 months of commencing PAH drug
treatment. Finally, we did not measure the blood levels
of PAH drugs to check patients’ adherence to taking
their medications or for unexpected drug interactions. It
is possible that older patients taking more medications
may not have taken their prescribed PAH drugs, and for
this reason future studies should confirm that these
drugs have been ingested.
Conclusions
This study shows that PAH patients with CV risk factors
have a less satisfactory response to PAH drug therapies
in terms of symptom severity and exercise capacity com-
pared with PAH patients without CV risk factors and
that this difference is not simply a result of age. With
the diagnosis of PAH being made with increasing fre-
quency in older patients, there is a need to further eluci-
date the mechanisms influencing the response to PAH
Figure 2. Number of cardiovascular comorbidities. Shown is
the number of cardiovascular risk factors in the PAH-CV and
PVH-CV groups. PAH: pulmonary arterial hypertension; CV:
cardiovascular risk factors; PVH-CV: PH related to left heart
disease with CV factors; PH: pulmonary hypertension; count:
number of patients.
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drug therapies and to define the best management strat-
egies in this population.
Source of Support: Nil.
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